|Member||Shares 31/12/2020||Options 31/12/2020|
|Dr. Gerd Zettlmeissl, Chairman of the Supervisory Board||0||0|
|Antoinette Hiebeler-Hasner, Deputy Chair of the Supervisory Board||0||0|
|Prof. Horst Domdey (until 16/12/2020)||39,125||0|
|Dr. Yita Lee (until 16/12/2020)||0||0|
|Dr. Anthony Man (since 16/12/2020)||0||0|
|Dr. Keith Manchester1)||0||0|
|Dr. Frank Mathias||20,197||46,0892)|
|Total Supervisory Board||59,322||46,089|
|Prof. Dr. Dolores J. Schendel, CEO3)||846,296||97,500|
|Dr. Kai Pinkernell, Member of the Executive Management Board||0||73,438|
|Axel Sven Malkomes, Member of the Executive Management Board||0||75,000|
|Total Executive Management Board||846,296||245,938|
|1) Dr. Manchester is a partner and Head of Life Sciences QVT Financial LP New York, USA. According to the latest voting rights announcement dated 8 June 2018, the funds managed by QVT hold 1,072,879 shares in Medigene AG.|
2) The stated number of options corresponds to 124,839 options prior to a capital reduction in 2013.
3) Prof. Schendel indirectly holds 846,296 Medigene shares in her capacity as Managing Director of DJSMontana Holding GmbH, which can be allocated to Prof. Schendel directly.